Baxter raises full-year profit forecast on robust demand for medical devices
Aug 6 (Reuters) -Baxter International BAX.N on Tuesday raised its annual profit expectations and beat Wall Street estimates for second-quarter profit on strong sales of its medical devices, driven by robust demand for medical care among patients.
Shares of the company rose 3% to $35.69 in premarket trading.
Medical device makers have been benefiting from increased demand for non-urgent surgeries such as hip and knee replacements over the past few quarters especially among older adults, who deferred these procedures during the pandemic.
Larger peers Stryker SYK.N and Boston Scientific BSX.N also raised their annual profit expectations last month, driven by demand for their medical and surgical devices.
Baxter now expects full-year adjusted profit between $2.93 and $3.01 per share, compared with its previous view of $2.88 to $2.98 per share. Analysts estimated $2.92 per share, according to LSEG data.
Revenue for the second-quarter ended June 30 came in at $3.81 billion, beating estimates of $3.76 billion.
Baxter's kidney care unit, which sells dialysis products, recorded sales of $1.12 billion for the reported quarter, compared with estimates of $1.14 billion.
The company said on Tuesday that it plans to separate the kidney care unit in late 2024 or early 2025. It had initially announced the spin-off plans last year amid supply-chain challenges and weak demand for dialysis operations.
Private equity firm Carlyle Group is in exclusive talks to acquire the kidney care unit for more than $4 billion, including debt, Reuters reported last month, citing a person familiar with the matter.
On an adjusted basis, the company earned 68 cents per share in the April-to-June quarter, compared with estimates of 66 cents per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
